Literature DB >> 2643223

Incidental and purposeful random donor blood transfusion. Sensitization and transplantation.

W W Pfaff1, R J Howard, J C Scornik, C Day, J Renderer, J Scott, R S Fennel, J C Peterson, D R Salomon, P R Patton.   

Abstract

We conducted a prospective study to gauge the frequency and degree of sensitization by transfusion and/or pregnancy in 797 candidates for first renal transplants. Sensitization was proportional to the number of blood transfusions. Multiple transfusions or a history of pregnancy without transfusions had similar effects on sensitization. The combination of transfusion and prior pregnancy resulted in sensitization of 1/3 of the candidates. Patients who were not sensitized and were accepted for 1-haplotype living-related donor grafts or first-cadaver donor grafts were transfused to receive a total of 5 units of packed red blood cells. Parous patients had an undue rate of antibody formation and alternate means of selecting and managing parous women are described. Nonparous candidates had a low rate of sensitization (8%) that did not prove an impediment to obtaining a transplant. Only 2% of prospective LRD graft recipients developed antibody against their intended donor. Transplant patients were generally managed with azathioprine and prednisone. One-haplotype LRD graft survival of protocol patients was 93.7% one year posttransplant, and 82.1% at 5 years. One-year CD graft survival was 77%. There was no reduction in graft survival when the interval between transfusion and transplantation exceeded one year. Random donor transfusion is effective in improving renal graft survival. Some recent multiinstitutional reports indicate a reduction or absence of the transfusion effect with current immunosuppression. Discarding blood transfusion as a preparation for transplantation may be ill-advised pending a prospective study.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2643223     DOI: 10.1097/00007890-198901000-00029

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

Review 1.  Current status of renal transplantation.

Authors:  M G Suranyi; B M Hall
Journal:  West J Med       Date:  1990-06

2.  Post-transplant blood transfusions and pediatric renal allograft outcomes.

Authors:  Priya Verghese; Kristen Gillingham; Arthur Matas; Srinath Chinnakotla; Blanche Chavers
Journal:  Pediatr Transplant       Date:  2016-10-06

3.  Washing red cells after leucodepletion does not decrease human leukocyte antigen sensitization risk in patients with chronic kidney disease.

Authors:  Antony Aston; Rebecca Cardigan; Saber Bashir; Susan Proffitt; Helen New; Colin Brown; Ri Liesner; Sylvia Hennem; Helen Nulty; Olivia Shaw; Robert Vaughan; Jon Jin Kim; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2014-04-29       Impact factor: 3.714

4.  A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD.

Authors:  Robert Toto; Jeffrey Petersen; Jeffrey S Berns; Eldrin Foster Lewis; Qui Tran; Matthew R Weir
Journal:  J Am Soc Nephrol       Date:  2020-12-07       Impact factor: 10.121

5.  Chapter 4: Red cell transfusion to treat anemia in CKD.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-08

6.  An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival.

Authors:  Juan C Scornik; Jonathan S Bromberg; Douglas J Norman; Mayank Bhanderi; Matthew Gitlin; Jeffrey Petersen
Journal:  BMC Nephrol       Date:  2013-10-10       Impact factor: 2.388

7.  Remodeling of active endothelial enhancers is associated with aberrant gene-regulatory networks in pulmonary arterial hypertension.

Authors:  Armando Reyes-Palomares; Mingxia Gu; Fabian Grubert; Ivan Berest; Silin Sa; Maya Kasowski; Christian Arnold; Mao Shuai; Rohith Srivas; Simon Miao; Dan Li; Michael P Snyder; Marlene Rabinovitch; Judith B Zaugg
Journal:  Nat Commun       Date:  2020-04-03       Impact factor: 17.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.